Background: Because HIV viral suppression is essential for optimal outcomes and prevention efforts, understanding trends and predictors is imperative to inform public health policy. Objective: To evaluate viral suppression trends in people living with HIV (PLWH), including the relationship of associated factors, such as demographic characteristics and integrase strand transfer inhibitor (ISTI) use. Design: Longitudinal observational cohort study. Setting: 8 HIV clinics across the United States. Participants: PLWH receiving clinical care. Measurements: To understand trends in viral suppression (≤400 copies/mL), annual viral suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited to 1 random test per person per year and using inverse probability of censoring weights to address loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH receiving antiretroviral therapy (ART) were used to examine associations between viral suppression or continuous viral load (VL) levels and demographic factors, substance use, adherence, and ISTI use. Results: Viral suppression increased from 32% in 1997 to 86% in 2015 on the basis of all tests among 31 930 PLWH. In adjusted analyses, being older (odds ratio [OR], 0.76 per decade [95% CI, 0.74 to 0.78]) and using an ISTI-based regimen (OR, 0.54 [CI, 0.51 to 0.57]) were associated with lower odds of having a detectable VL, and black race was associated with higher odds (OR, 1.68 [CI, 1.57 to 1.80]) (P < 0.001 for each). Similar patterns were seen with continuous VL levels; when analyses were limited to 2010 to 2015; and with adjustment for adherence, substance use, or depression. Limitation: Results are limited to PLWH receiving clinical care. Conclusion: HIV viral suppression rates have improved dramatically across the United States, which is likely partially attributable to improved ART, including ISTI-based regimens. However, disparities among younger and black PLWH merit attention. Primary Funding Source: National Institutes of Health.
Background: Because HIV viral suppression is essential for optimal outcomes and prevention efforts, understanding trends and predictors is imperative to inform public health policy. Objective: To evaluate viral suppression trends in people living with HIV (PLWH), including the relationship of associated factors, such as demographic characteristics and integrase strand transfer inhibitor (ISTI) use. Design: Longitudinal observational cohort study. Setting: 8 HIV clinics across the United States. Participants: PLWH receiving clinical care. Measurements: To understand trends in viral suppression (≤400 copies/mL), annual viral suppression rates from 1997 to 2015 were determined. Analyses were repeated with tests limited to 1 random test per person per year and using inverse probability of censoring weights to address loss to follow-up. Joint longitudinal and survival models and linear mixed models of PLWH receiving antiretroviral therapy (ART) were used to examine associations between viral suppression or continuous viral load (VL) levels and demographic factors, substance use, adherence, and ISTI use. Results: Viral suppression increased from 32% in 1997 to 86% in 2015 on the basis of all tests among 31 930 PLWH. In adjusted analyses, being older (odds ratio [OR], 0.76 per decade [95% CI, 0.74 to 0.78]) and using an ISTI-based regimen (OR, 0.54 [CI, 0.51 to 0.57]) were associated with lower odds of having a detectable VL, and black race was associated with higher odds (OR, 1.68 [CI, 1.57 to 1.80]) (P < 0.001 for each). Similar patterns were seen with continuous VL levels; when analyses were limited to 2010 to 2015; and with adjustment for adherence, substance use, or depression. Limitation: Results are limited to PLWH receiving clinical care. Conclusion:HIV viral suppression rates have improved dramatically across the United States, which is likely partially attributable to improved ART, including ISTI-based regimens. However, disparities among younger and black PLWH merit attention. Primary Funding Source: National Institutes of Health.
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: David A Wohl; Calvin Cohen; Joel E Gallant; Anthony Mills; Paul E Sax; Edwin Dejesus; Andrew Zolopa; Hui C Liu; Andrew Plummer; Kirsten L White; Andrew K Cheng; Martin S Rhee; Javier Szwarcberg Journal: J Acquir Immune Defic Syndr Date: 2014-03-01 Impact factor: 3.731
Authors: Jacek Skarbinski; Eli Rosenberg; Gabriela Paz-Bailey; H Irene Hall; Charles E Rose; Abigail H Viall; Jennifer L Fagan; Amy Lansky; Jonathan H Mermin Journal: JAMA Intern Med Date: 2015-04 Impact factor: 21.873
Authors: Katharine A Bradley; Kristen R Bush; Amee J Epler; Dorcas J Dobie; Tania M Davis; Jennifer L Sporleder; Charles Maynard; Marcia L Burman; Daniel R Kivlahan Journal: Arch Intern Med Date: 2003-04-14
Authors: R Fredericksen; P K Crane; J Tufano; J Ralston; S Schmidt; T Brown; D Layman; R D Harrington; S Dhanireddy; T Stone; W Lober; M M Kitahata; H M Crane Journal: J AIDS HIV Res Date: 2012-02-28
Authors: Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier Journal: Ann Intern Med Date: 2014-10-07 Impact factor: 25.391
Authors: Catherine R Lesko; Alexander P Keil; Anthony T Fojo; Geetanjali Chander; Bryan Lau; Richard D Moore Journal: Am J Epidemiol Date: 2019-10-01 Impact factor: 4.897
Authors: Nicole E Winchester; Frank Maldarelli; Yolanda Mejia; Nicola Dee; Robin Dewar; Elizabeth Laidlaw; Safia S Kuriakose; Pamela Stoll; Michael Proschan; H Clifford Lane; Alice K Pau Journal: Clin Infect Dis Date: 2020-03-03 Impact factor: 9.079
Authors: Yu Liu; Vincent M B Silenzio; Robertson Nash; Patrick Luther; Jose Bauermeister; Sten H Vermund; Chen Zhang Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: S A Safren; A Harkness; J S Lee; B G Rogers; N A Mendez; J F Magidson; A J Blashill; S Bainter; A Rodriguez; G Ironson Journal: AIDS Behav Date: 2020-11
Authors: Maria L Ekstrand; Elsa Heylen; Matilda Pereira; Jacob D'Souza; Shoba Nair; Amanda Mazur; Ranjani Shamsundar; B N Ravi Kumar; Sara Chandy Journal: AIDS Behav Date: 2020-07
Authors: David Goodman-Meza; Steve Shoptaw; Robert E Weiss; Terry Nakazono; Nina T Harawa; Sae Takada; Wendy H Garland; William E Cunningham Journal: Drug Alcohol Depend Date: 2019-07-16 Impact factor: 4.492
Authors: John A Sauceda; Nadra E Lisha; Samantha E Dilworth; Mallory O Johnson; Katerina A Christopoulos; Troy Wood; Kimberly A Koester; W Christopher Mathews; Richard D Moore; Sonia Napravnik; Kenneth H Mayer; Heidi M Crane; Rob J Fredericksen; Michael J Mugavero; Torsten B Neilands Journal: Health Psychol Date: 2020-04-13 Impact factor: 4.267